Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in Japan.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Onitsuka Toshiaki, Okada Tsuyoshi, Hasegawa Naomi, Tsuboi Takashi, Iga Jun-Ichi, Yasui-Furukori Norio, Yamada Naoki, Hori Hikaru, Muraoka Hiroyuki, Ohi Kazutaka, Ogasawara Kazuyoshi, Ochi Shinichiro, Takeshima Masahiro, Ichihashi Kayo, Fukumoto Kentaro, Iida Hitoshi, Yamada Hisashi, Furihata Ryuji, Makinodan Manabu, Takaesu Yoshikazu, Numata Shusuke, Komatsu Hiroshi, Hishimoto Akitoyo, Kido Mikio, Atake Kiyokazu, Yamagata Hirotaka, Kikuchi Saya, Hashimoto Naoki, Usami Masahide, Katsumoto Eiichi, Asami Takeshi, Kubota Chika, Matsumoto Junya, Miura Kenichiro, Hirano Yoji, Watanabe Koichiro, Inada Ken, Hashimoto Ryota
Аннотация
METHODS: The present study used data from the project for the Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment from 94 facilities in Japan. The LAI group included patients who received any LAI, and the non-LAI group included patients who took only OAP medications at discharge. The participants of this study were 2518 schizophrenia patients (263 in the LAI group and 2255 in the non-LAI group) who received inpatient treatment and had prescription information at discharge between 2016 and 2020.
RESULTS: This study revealed significantly higher rates of polypharmacy antipsychotics, number of antipsychotics, and chlorpromazine equivalents in the LAI group than in the non-LAI group. In contrast, the LAI group showed lower rate of concomitant use of hypnotic and/or antianxiety medication than the non-LAI group.
CONCLUSIONS: Presenting these real-world clinical results, we want to encourage clinicians to keep monotherapy in mind for the treatment of schizophrenia, especially by reducing concomitant use of antipsychotics in the LAI group and reducing hypnotic and/or antianxiety medication in the non-LAI group.